Making Health and Well-Being More Accessible

Apr 13, 2020 by Elaine Cohen

Ensuring widespread health and well-being is fundamental to global prosperity. At Orbia, we use our unique capabilities across our different business groups to advance solutions that make communities healthier and more resilient. Orbia is the leading global supplier of polymers used in essential medical equipment such as IV bags, tubes, oxygen masks and a range of medical grade PVC enhancements for hospitals and clinics, as well as a manufacturer of the chlorine used in many life-sustaining applications. In addition, Orbia’s Fluor business group leads global production of the fluorine-based medical propellants used to deliver life-saving medications in metered-dose inhalers and similar respiratory devices.

“The versatility and wide application of fluorine-based products enables us to be at the center of many innovations that can help us advance life around the world. With our efforts in next-generation medical propellants, refrigerants with lower global warming potential and fluorinated additives for energy storage, we are at the forefront of developing solutions for a sustainable future. At the same time, as a responsible operator, we are making our mining and manufacturing processes safer and more efficient.”

- Sameer Bharadwaj, President, Fluor & Compounds

Supporting human and environmental health

Today, Koura supplies over 70% of the fluorine-based medical propellants used in the metered dose inhalers (MDIs) that ensure millions of asthma patients worldwide can breathe easily. In a move-the-needle moment on the journey to sustainable and conscientious therapies, after several years of dedicated research and development, Koura introduced Zephex® 152a (1,1-difluoroethane), a new propellant gas will deliver more than 90 percent reduction in Global Warming Potential for pressurized MDIs, as compared to current offerings. In early 2020, the U.S. Food and Drug Administration (FDA) approved progress to clinical trials.

Working with Chiesi Farmaceutici, an international pharmaceutical company based in Italy, Koura is now advancing the development of safer, cleaner, and greener Zephex® 152a-powered MDIs with a slated market launch date of 2025. Chiesi plans to invest €350 million to bring these new formulations to market, while Koura has committed a multimillion-dollar investment in a pharmaceutical-grade laboratory facility in the U.K. to develop Zephex® 152a to the requirements of the FDA and worldwide regulatory agencies as well as support further propellant development activities.

“We believe protecting patient health and the environment should not be a matter of compromise. We are proud to supply both pMDI and DPI inhalers and to have taken decisive and ambitious action to ensure patients can continue to access the inhaler options that best suit their needs, whilst innovating to find the most environmentally conscious solutions available.”

- Ugo Di Francesco, CEO, Chiesi Group

Want to learn more about Koura solutions?